Allergo Journal International最新文献

{"title":"Aspergillus-associated diseases from an infectious diseases and allergological perspective","authors":"Jannik Stemler,&nbsp;Julia A. Nacov,&nbsp;Rosanne Sprute,&nbsp;Oliver A. Cornely,&nbsp;Marcus Joest,&nbsp;Sven Becker,&nbsp;Ludger Klimek","doi":"10.1007/s40629-024-00286-9","DOIUrl":"10.1007/s40629-024-00286-9","url":null,"abstract":"<div><p><i>Aspergillus</i>-associated diseases are rare and pose challenges for practitioners. Diagnosis is complex and requires rational, targeted, and multidisciplinary collaboration, as well as a high degree of expertise and an individualized approach. For the infectious diseases physician, the focus is on the question of infection or colonization. In severely immunocompromised patients, invasive aspergillosis occurs, which most frequently affects the lungs (IPA) and is characterized by invasive, destructive growth. This acute clinical picture is associated with a high mortality rate. Chronic pulmonary aspergillosis (CPA) develops on the basis of pre-existing changes in lung structure caused by other pulmonary diseases and often requires surgical treatment. Another chronic form is allergic bronchopulmonary aspergillosis (ABPA). It is often associated with bronchiectasis in patients with bronchial asthma or cystic fibrosis. Sinus mycoses are divided into non-invasive and invasive forms, which can occur in immunocompromised patients and most commonly affect the maxillary sinus. Here, local surgical measures are an obligatory part of treatment, whereas the non-invasive form usually has an allergic component. In addition, drug-based antifungal and/or anti-inflammatory therapy is used for all entities.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 4","pages":"140 - 152"},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00286-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140214422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of a fast challenge test with iodinated contrast media in allergic patients with anaphylaxis","authors":"Francisco Vega MD PhD,&nbsp;Azahara Lopez-Raigada MD,&nbsp;M. Victoria Mugica MD PhD,&nbsp;Rodrigo Jimenez-Saiz PhD,&nbsp;Carlos Blanco MD PhD","doi":"10.1007/s40629-024-00285-w","DOIUrl":"10.1007/s40629-024-00285-w","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 6","pages":"190 - 193"},"PeriodicalIF":0.0,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140263063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crowd-sourced symptom data in pollen allergy: testing a novel study approach for assessing the efficacy of food supplements","authors":"Lukas Dirr,&nbsp;Katharina Bastl,&nbsp;Maximilian Bastl,&nbsp;Johannes M. Bouchal,&nbsp;Uwe E. Berger,&nbsp;Friðgeir Grímsson","doi":"10.1007/s40629-024-00283-y","DOIUrl":"10.1007/s40629-024-00283-y","url":null,"abstract":"<p>Pollen allergy can have a significant impact on a person’s quality of life. Recently, food supplements have gained in importance for persons suffering from pollen allergy. Still, there is not much research data on the efficacy of food supplements and the experienced relief, especially when choosing study designs that require less effort than randomized controlled trials (RCT).</p><p>A food supplement containing an <i>Astragalus membranaceus</i> root extract was administered to 328 voluntary participants during the 2018 birch, grass and ragweed pollen season in Austria. Participants documented their symptoms and medication intake in the online Patients Hay-fever Diary (PHD). All participants were asked to answer a quality-of-life questionnaire at the end of the study. Alongside with the adherence rate the overall symptom load index (SLI) and the nasal symptoms of the participants were monitored and compared to a filtered group of users from the PHD.</p><p>The adherence rates range from 32.8% to 77.3%. Additional data like a quality-of-life questionnaire and the mean overall/nasal SLI showed differences between participants and the baseline. However, they were only statistically significant for the ragweed pollen season and the nasal symptoms.</p><p>The study design relied on the evaluation of crowd-source symptom data alone by comparing the participants with a baseline. The participant adherence turned out lower than expected; however a trend for reduced symptoms was found and is also supported by the quality-of-life questionnaire.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 6","pages":"180 - 189"},"PeriodicalIF":0.0,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-024-00283-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140489593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of the combination nasal spray olopatadine hydrochloride-mometasone furoate in the treatment of allergic rhinitis","authors":"Ludger Klimek,&nbsp;Felix Klimek,&nbsp;Christoph Bergmann,&nbsp;Jan Hagemann,&nbsp;Mandy Cuevas,&nbsp; Sven Becker MHBA","doi":"10.1007/s40629-023-00282-5","DOIUrl":"10.1007/s40629-023-00282-5","url":null,"abstract":"<div><h3>Introduction</h3><p>Pharmacotherapy is the main pillar in the treatment of allergic rhinitis. While antihistamines (AH) and intranasal glucocorticosteroids (INCS) have long been part of the therapeutic standard, a pharmacological combination of both active substances in a nasal spray has so far only been implemented and made available in two preparations in Germany. Recently, an intranasal olopatadine hydrochloride-mometasone furoate (Olo-Mom) combination was introduced as a nasal spray for the treatment of seasonal and perennial allergic rhinitis.</p><h3>Methods</h3><p>In a literature search, treatment options for allergic rhinitis were analyzed and the available evidence was determined by searching Medline, PubMed, and the national and international study (ClinicalTrials.gov) and guideline registers and the Cochrane Library. Human studies published on the topic in the period up to and including August 2023 were taken into account.</p><h3>Results</h3><p>Based on the international literature and previous experience, the results are summarized and recommendations are given. The drugs used in the pharmacotherapy of AR primarily include INCS, intranasal and oral AH, leukotriene antagonists, intranasal cromoglicic acid preparations, intranasal and oral vasoconstrictors, and nasal rinses. For patients with intermittent and persistent allergic rhinitis, INCS are the first-line therapy, but in many patients they do not work sufficiently or quickly enough. The fixed combination Olo-Mom nasal spray showed significant improvements in the Reflective Total Nasal Symptom Score (rTNSS) in two phase II clinical trials with twice-daily and once-daily administration. In phase III studies, Olo-Mom nasal spray administered twice daily showed significant improvements in rTNSS compared to placebo, olopatadine monotherapy, and mometasone monotherapy.</p><h3>Conclusion</h3><p>In summary, AH and INCS will remain the main groups of active ingredients in the treatment of allergic rhinitis in the future. In combination preparations such as the new combination nasal spray olopatadine hydrochloride-mometasone furoate, they are highly effective and safe, thus opening up new perspectives, especially for patients with moderate and severe allergic rhinitis from the age of 12 years.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 1","pages":"9 - 19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00282-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139609126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic gap due to missing patch test allergens—status quo and possible scenarios for mitigation","authors":"Vera Mahler","doi":"10.1007/s40629-023-00281-6","DOIUrl":"10.1007/s40629-023-00281-6","url":null,"abstract":"<p>According to European Directive 2001/83/EC, test and therapeutic allergens are medicinal products in all Member States of the European Union. This applies equally to prick test and to patch test (PT) allergens (haptens). All test allergens commercially marketed in Germany are finished medicinal products requiring marketing authorization (MA). Currently, 211 PT substances are authorized in Germany, and an additional 59 are in an ongoing MA process and are marketable under a transitional provision until a decision on MA is made. The regulatory guidance (CMDh/399/2019) of the Co-ordination Group for Mutual Recognition and Decentralized Procedures—Human (CMDh), published in July 2020, specifies the regulatory requirements for different allergen products. Due to differences in origin and exposure, use, mode of action, and safety risks, the guideline clearly differentiates between products with active ingredients of biological origin (allergen extracts from natural source materials) and products with active ingredients of non-biological origin (hapten-based PT substances). Currently, guideline-compliant patch testing is hampered by the lack of numerous commercial PT allergens from the standard and special test series. Background and possible scenarios for mitigation are presented here.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 2","pages":"67 - 72"},"PeriodicalIF":0.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00281-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139624069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tattoo allergy—diagnosis on a circuitous route?","authors":"Steffen Schubert,&nbsp;Carina Wolf,&nbsp; Ines Schreiver,&nbsp; Katherina Siewert,&nbsp; Uwe Karst","doi":"10.1007/s40629-023-00280-7","DOIUrl":"10.1007/s40629-023-00280-7","url":null,"abstract":"<div><h3>Background</h3><p>Decorative tattoos and permanent make-up have been gaining popularity for years. Increasingly, intolerance reactions occur.</p><h3>Methods</h3><p>Literature search of PubMed and reference books on diagnostic and treatment options for tattoo complications.</p><h3>Results</h3><p>At least one third of persistent intolerance reactions to tattoos are allergic reactions. The diagnostic work-up should include the tattoo ink used and, particularly in cases of scattered eczema, other products applied. Pigments penetrate very poorly into the epidermis and are not available as commercial test preparations. Consequently, patch tests very often show (false) negative results in affected individuals. Allergological individual diagnosis and assessment of clinical relevance are rarely possible as the chemical composition of the culprit tattoo ink is usually unknown.</p><h3>Discussion</h3><p>Diagnosis of tattoo allergy is challenging. The IVDK Tattoo Study 2.0 enables the identification of metals and pigments in skin samples, the preparation of individual patch test preparations with pigments, and the investigation of specific T lymphocytes in blood samples. In addition, assessment of the clinical relevance can be improved by exposure data and results of laboratory diagnostics.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 2","pages":"60 - 66"},"PeriodicalIF":0.0,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138949968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of systemic inflammation markers in patients with rhinitis","authors":"Sümeyra Alan Yalim,&nbsp;Ayse Füsun Kalpaklıoglu,&nbsp;Ayşe Baccıoglu,&nbsp;Merve Poyraz,&nbsp;Gulistan Alpagat,&nbsp;Betul Dumanoglu","doi":"10.1007/s40629-023-00277-2","DOIUrl":"10.1007/s40629-023-00277-2","url":null,"abstract":"<p>Rhinitis affects the majority of the population. It may generate localized nasal mucosal inflammation via allergic (AR) or nonallergic (NAR) processes, but it is unknown if this might also result in systemic inflammation, which can raise morbidity and death. Using current serum inflammatory markers, we sought to investigate systemic inflammation in patients with chronic rhinitis.</p><p>In this retrospective case–control study, we included 439 patients with newly diagnosed AR (<i>n</i> = 179), NAR (<i>n</i> = 157), and 103 healthy individuals. Inflammation-related blood parameters were collected as lymphocyte/monocyte ratio (LMR), neutrophil/lymphocyte ratio (NLR), eosinophil/neutrophil ratio (ELR), and systemic immune inflammation index (SII).</p><p>All groups were similar in terms of age, gender, and body mass index. Neutrophil counts were significantly higher both in AR and NAR groups compared to controls (4.51 ± 0.09, 4.54 ± 0.1 vs. 3.73 ± 0.1, <i>p</i> &lt; 0.001). NLR (1.91 ± 0.56, 1.89 ± 0.61, 1.61 ± 0.59, <i>p</i> &lt; 0.001), LMR (5.76 ± 0.17, 5.93 ± 0.17, 5.1 ± 0.15, <i>p</i> = 0.005), ELR (0.1335 ± 0.007, 0.0999 ± 0.006, 0.12 ± 0.009, <i>p</i> = 0.003), SII (533.3 ± 16.6, 558.1 ± 20.9, 479.9 ± 22.2, <i>p</i> = 0.035), and CRP (1.44 ± 0.09, 1.67 ± 0.09, 0.87 ± 0.04, <i>p</i> &lt; 0.001) were significantly higher in AR and NAR groups than the controls, respectively. SII (r = 0.146, <i>p</i> = 0.007) and ELR (r = 0.254, <i>p</i> &lt; 0.001) were correlated with the presence of asthma.</p><p>We found that systemic circulation of inflammatory cells was significantly increased in rhinitis with/without allergy compared to the control group. This study showed that not only AR, but also NAR triggers a systemic increase of inflammation which supports the link between rhinitis and comorbid conditions such as asthma. Therefore, effective treatment may be suggested for local inflammation and its systemic manifestations.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 1","pages":"24 - 31"},"PeriodicalIF":0.0,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139173394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of the systemic immune inflammation index and systemic inflammatory response index on omalizumab drug survival in chronic spontaneous urticaria","authors":"Adriano Fabi BMed,&nbsp;Stefan Milosavljevic MSc PhD,&nbsp;Claudia C. V. Lang MD,&nbsp;Carole Guillet MD,&nbsp; Peter Schmid-Grendelmeier MD","doi":"10.1007/s40629-023-00278-1","DOIUrl":"10.1007/s40629-023-00278-1","url":null,"abstract":"<div><h3>Background</h3><p>Omalizumab is recommended as adjunctive therapy for antihistamine-refractory chronic spontaneous urticaria (CSU). However, its long-term effectiveness is understudied. The systemic immune-inflammation index (SII) and the systemic inflammatory response index (SIRI) have shown prognostic value in cancer, strokes, and other diseases.</p><h3>Objectives</h3><p>This study aimed to evaluate the long-term effectiveness of omalizumab in CSU patients while investigating potential associations of SII and SIRI with the drug survival of omalizumab.</p><h3>Methods</h3><p>A retrospective study was conducted using patient data from the electronic hospital database, including patients with CSU treated with omalizumab between January 2018 and May 2021. Drug survival curves were visualized using Kaplan-Meier survival analysis. and Cox regression was utilized to assess potential associations.</p><h3>Results</h3><p>A total of 109 CSU treated with omalizumab at the University Hospital of Zurich were included. The mean drug survival was 13.6 ± 10.9 months. The mean SII and SIRI were 796.1 ± 961.3 and 2.1 ± 3.1, respectively. The multivariate model revealed that SIRI (<i>p</i> = 0.098) was a more robust predictor of omalizumab’s drug survival than SII (<i>p</i> = 0.367), while concurrent autoimmune disease or baseline immunoglobulin E (IgE) levels showed no significant impact.</p><h3>Conclusion</h3><p>This study suggests the potential utility of SIRI as a superior predictive indicator for omalizumab’s drug survival in CSU patients compared to SII. Concomitant autoimmune disease or baseline IgE levels did not significantly affect the drug’s effectiveness.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 1","pages":"32 - 40"},"PeriodicalIF":0.0,"publicationDate":"2023-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00278-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139008099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful desensitization to asfotase alfa in hypophosphatasia: a case report and IgE-mediated mechanism confirmation","authors":"Emilio Narváez-Fernández,&nbsp;Magdalena Lluch-Bernal,&nbsp;Ana Fiandor,&nbsp;Pilar Aguado,&nbsp;Carolina Tornero,&nbsp;Miguel González-Muñoz,&nbsp;Rosario Cabañas","doi":"10.1007/s40629-023-00279-0","DOIUrl":"10.1007/s40629-023-00279-0","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 3","pages":"94 - 96"},"PeriodicalIF":0.0,"publicationDate":"2023-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138589377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contact allergy to medical devices","authors":"Nicola Wagner","doi":"10.1007/s40629-023-00276-3","DOIUrl":"10.1007/s40629-023-00276-3","url":null,"abstract":"<div><h3>Background</h3><p>Medical devices are not subject to any legal obligation to declare ingredients. With an increasing number of available medical devices, increasing reports of contact allergies to these devices result in a more difficult, delayed or lack of diagnosis of the trigger.</p><h3>Methods</h3><p>Elaborate chemical methods, such as gas chromatography–mass spectroscopy, were able to detect novel contact allergens in medical devices.</p><h3>Results</h3><p>Diabetic patients requiring insulin benefit from sophisticated glucose sensor measurement systems and insulin pump systems, but are limited in their choices by the development of contact allergy. Potential contact allergens in medical adhesives, plasters, and wound dressings require extensive diagnostic testing. Contact allergic reactions to cardiac electronic implants are rare. The potential relevance of a contact allergic reaction to endoluminal stents to restenosis of the treated vascular territory is discussed. Contact dermatitis to medical gloves is usually due to the vulcanization accelerators. Mouth–nose protective or FFP2 mask-associated eczema is often irritant, very rarely allergic in origin.</p><h3>Conclusion</h3><p>With continued development of medical devices, new contact allergens are introduced. The declaration of their ingredients is necessary for rapid diagnosis and future prevention.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"33 2","pages":"54 - 59"},"PeriodicalIF":0.0,"publicationDate":"2023-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00276-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135291163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}